
IFRX
Healthcare · Biotechnology · $172.4M market cap
$1.17-0.07 (-5.6%)Nov 13, 4:20 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +34.8% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 3, 2026 | Before the open | -0.07 | -0.02 | +71.4% |
| Aug 6, 2026 | Before the open | -0.08 | -0.11 | -37.5% |
| May 13, 2026 | Time not confirmed | -0.18 | -0.08 | +55.6% |
| Mar 19, 2026 | Before the open | -0.15 | -0.15 | 0.0% |
| Nov 10, 2025 | Before the open | -0.12 | -0.18 | -50.0% |
| Aug 7, 2025 | Before the open | -0.24 | -0.24 | 0.0% |
| May 7, 2025 | Before the open | -0.18 | -0.13 | +27.8% |
| Mar 20, 2025 | Time not confirmed | -0.25 | -0.09 | +64.2% |
| Nov 8, 2024 | Before the open | -0.25 | -0.30 | -20.0% |
| Aug 8, 2024 | Before the open | -0.18 | -0.24 | -33.3% |
| May 8, 2024 | Before the open | -0.22 | -0.17 | +22.7% |
| Mar 21, 2024 | Before the open | -0.18 | -0.27 | -50.0% |
| Nov 1, 2023 | Before the open | -0.23 |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the…
| -0.13 |
| +43.5% |
| Aug 10, 2023 | Before the open | -0.32 | -0.14 | +56.3% |
| May 11, 2023 | Before the open | -0.27 | -0.25 | +7.4% |
| Mar 22, 2023 | Before the open | -0.25 | -0.18 | +28.0% |
| Nov 9, 2022 | Before the open | -0.35 | -0.18 | +48.6% |
| Aug 5, 2022 | Before the open | -0.32 | 0.01 | +103.1% |
| May 12, 2022 | Before the open | -0.34 | -0.32 | +5.9% |
| Mar 24, 2022 | Before the open | -0.22 | -0.32 | -45.5% |
| Nov 5, 2021 | Before the open | -0.34 | -0.27 | +20.6% |
| Aug 5, 2021 | Before the open | -0.21 | -0.33 | -57.1% |
| May 12, 2021 | Before the open | -0.22 | -0.18 | +18.2% |
| Mar 25, 2021 | Before the open | -0.22 | -0.32 | -45.5% |
| Oct 29, 2020 | Before the open | -0.33 | -0.25 | +24.2% |
| Jul 30, 2020 | Before the open | -0.36 | -0.38 | -5.6% |
| May 21, 2020 | Before the open | -0.52 | -0.32 | +38.5% |
| Nov 7, 2019 | Before the open | -0.54 | -0.56 | -3.7% |
| Aug 14, 2019 | After the close | -0.46 | -0.59 | -28.3% |
| May 23, 2019 | Before the open | -0.51 | -0.38 | +25.5% |
| Mar 28, 2019 | Before the open | -0.36 | -0.39 | -8.3% |
| Nov 21, 2018 | Before the open | -0.33 | -0.30 | +9.1% |
| Aug 9, 2018 | Before the open | -0.31 | -0.10 | +67.7% |
| May 17, 2018 | Before the open | -0.28 | -0.40 | -42.9% |
| Mar 29, 2018 | Before the open | -0.25 | -2.16 | -764.0% |